NeuClone Pharmaceuticals has announced that its NeuCeptin (trastuzumab) proposed biosimilar to Herceptin has successfully met all of its primary and secondary endpoints in a Phase I clinical trial. NeuCeptin is “one of several biosimilars developed in partnership between NeuClone and the Serum Institute of India.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?